
James Ip, MD, discusses his new analysis of the RAPID portion of the phase 3 NODE-301 trial, which indicates the efficacy of etripamil in patients who have undergone an incomplete ablation.

James Ip, MD, is a professor and cardiologist at Weill Cornell Medicine.

James Ip, MD, discusses his new analysis of the RAPID portion of the phase 3 NODE-301 trial, which indicates the efficacy of etripamil in patients who have undergone an incomplete ablation.

Ip highlights the uniform safety of patient-administered etripamil nasal spray across a series of phase 2 and 3 studies.